| Filed On | Filing |
|---|---|
| 30 Oct 2025 |
8-K/A: Regulation FD Disclosure; Other Events
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day |
| 19 Dec 2022 |
8-K/A: Regulation FD Disclosure; Other Events
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing |
| 19 Aug 2020 |
8-K/A: Submission of Matters to a Vote of Security Holders
On August 12, 2020, Wave Life Sciences Ltd. (the “Company”) held its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”). Of the 36,728,649 ordinary shares issued and outstanding and eligible to vote as of the meeting date... |
| 16 Aug 2019 |
8-K/A: Submission of Matters to a Vote of Security Holders
On August 8, 2019, Wave Life Sciences Ltd. (the “Company”) held its 2019 Annual General Meeting of Shareholders (the “Annual Meeting”). Of the 34,280,578 ordinary shares issued and outstanding and eligible to vote as of the meeting date ... |
| 17 Aug 2017 |
8-K/A: Submission of Matters to a Vote of Security Holders
On August 10, 2017, the Company held its Annual Meeting. Of the 27,760,214 ordinary shares issued and outstanding and eligible to vote as of the meeting date of August 10, 2017, a quorum of 25,534,687 ordinary shares, or 91.98%, of the e... |
Loading...